Viatris Inc. (VTRS) fair value analysis
S&P 500 · Updated 2026-09-07
Viatris Inc. is a global pharmaceutical company that develops, manufactures, and distributes generic and branded medicines across multiple therapeutic areas. The company operates in markets throughout North America, Europe, Asia, and other regions worldwide.
Valuation status
Awaiting full valuationVTRS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $16.88
- Sector
- Healthcare
- 12-month range
- $10.36–$17.63
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- Margin trend
- Contracting
- Revenue growth
- Declining
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
- DCF cross-check
- Overvalued
What our data shows for VTRS
- Our model validated 2 trailing price-to-earnings windows for VTRS, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $10.36–$17.63.
- The 14-day relative strength index sits at a neutral 45.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for VTRS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent VTRS news
TickrTrends' derived news-sentiment signal for VTRS is currently leaning positive, computed from recent coverage.
- Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks (finance.yahoo.com, 2026-09-02)
TickrTrends take: Vitros Corporation trades under 20 dollars per share and operates within the Healthcare sector, positioning it among stocks that may attract attention from prominent investors seeking lower-priced opportunities in this industry. TickrTrends is currently awaiting full valuation analysis for VTRS, meaning a comprehensive assessment of its fundamental value relative to market price has not yet been completed. Investors focused on valuation metrics should monitor when a complete TickrTrends verdict becomes available, as this will provide data-driven perspective on whether the stock's current price reflects its underlying business value. - Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overvalued (gurufocus.com, 2026-08-28)
TickrTrends take: VTRS shares declined in recent trading while remaining classified as overvalued according to GF Value metrics, which aligns with TickrTrends' current position of awaiting full valuation on the stock. For investors focused on valuation dynamics in the Healthcare sector, the combination of downward price movement and persistent overvaluation signals warrants attention to whether the stock may be moving toward a more attractive entry point or if valuation concerns will continue to weigh on performance. The gap between current market price and intrinsic value estimates remains a key metric to monitor as additional fundamental data emerges. - Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score (gurufocus.com, 2026-08-27)
TickrTrends take: Viatris Inc trades in the Healthcare sector with a TickrTrends valuation status currently marked as awaiting full valuation, meaning comprehensive fundamental metrics remain under review. The company's 60 GF Score suggests moderate quality characteristics, which becomes relevant context once complete valuation data is available for comparison against sector peers. Investors tracking valuation developments should monitor when TickrTrends completes its full assessment, as this will provide the analytical foundation needed to contextualize the quality score within pricing and value metrics.
What people are saying
Follow the VTRS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — TickrTrends' derived indicators for VTRS in the Healthcare sector showed a notable shift this week, with the DCF cross-check band moving from fairly valued to overvalued. The current valuation verdict remains awaiting full valuation as additional analysis continues.
- 2026-09-06 — VTRS, a healthcare sector company, showed movement in its derived valuation indicators this week. The DCF cross-check band shifted from an undervalued position to fairly valued, reflecting updated assumptions in the discounted cash flow analysis. The full valuation verdict remains under review pending completion of comprehensive assessment metrics.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is VTRS stock undervalued?
VTRS does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VTRS's TickrTrends verdict?
VTRS is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is VTRS overbought or oversold?
VTRS's 14-day RSI is in neutral territory - neither overbought nor oversold.